Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|August 2, 2018
- Pharmaceutical Technology-08-02-2018
- Volume 42
- Issue 8
Advanced Paddle Blender for Labs
Ross, Charles & Son’s Laboratory Paddle Blender offers advanced features for automated powder blending and liquid spraying operation with recipe management.
Ross, Charles & Son’s Laboratory Paddle Blender offers advanced features for automated powder blending and liquid spraying operation with recipe management. Features include full vacuum capability, a pneumatic powder charging port, and a liquid delivery spray system to promote batch-to-batch consistency. The 1-ft3, 42P-1SS model is constructed entirely of United States stainless steel type 304 with 150-grit interior finish and driven by a 1-hp, totally enclosed, fan-cooled motor.
Touchscreen programmable logic controller recipe controls are housed inside a National Electrical Manufacturers Association-classified 4X stainless steel enclosure, allowing for indoor or outdoor use. The company states that an interchangeable ribbon agitator can be supplied with any new paddle blender for increased versatility. Both paddle and ribbon agitators are used in the preparation of dry solid-solid mixes and can accommodate minor liquid additions.
Articles in this issue
about 8 years ago
Pharmaceuticals in the Environmentabout 8 years ago
E&L Risk Assessment for Biologic Drug Productsabout 8 years ago
Exploring a Modern Control Strategy for Wurster Coatingabout 8 years ago
Key Considerations in Multilayer Tabletingabout 8 years ago
FDA is Not Playing Games with Biosimilarsabout 8 years ago
Increasing API Complexity Drives Demand for Cryogenic Capabilitiesabout 8 years ago
Benchtop Sample Preparation Stationabout 8 years ago
Single-Use Electromagnetic Flow Meterabout 8 years ago
AODD Pump Alternative to Plastic PumpsRelated to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.